Safety of a Four‐factor Prothrombin Complex Concentrate Versus Plasma for Vitamin K Antagonist Reversal: An Integrated Analysis of Two Phase IIIb Clinical Trials

OBJECTIVES: Clinicians often need to rapidly reverse vitamin K antagonists (VKAs) in the setting of major hemorrhage or urgent need for surgery. Little is known about the safety profile of the traditional reversal agent, plasma, or the newly approved agent, four‐factor prothrombin complex concentrat...

Descripción completa

Detalles Bibliográficos
Autores principales: Milling, Truman J., Refaai, Majed A., Sarode, Ravi, Lewis, Brandon, Mangione, Antoinette, Durn, Billie L., Harman, Amy, Lee, Martin L., Goldstein, Joshua N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Contributions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071715/
https://www.ncbi.nlm.nih.gov/pubmed/26822172
http://dx.doi.org/10.1111/acem.12911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071715/
https://www.ncbi.nlm.nih.gov/pubmed/26822172
http://dx.doi.org/10.1111/acem.12911

Ejemplares similares